Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in India will almost double by 2013, growing from $27.7 million in 2008 to $52.1 million in 2013. This growth will be fueled by an increased uptake of antimetabolites and targeted therapies. In fact, the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitor drug classes will dominate the market throughout the forecast period with a combined market share of 55 percent by 2013.
The new Emerging Markets report entitled Non-Small-Cell Lung Cancer in India also finds that Western-branded drug sales in India's non-small-cell lung cancer market will command 54 percent by 2013. Even though Western-branded small-molecule agents are facing fierce competition from domestic products, including gefitinib (in the U.S. known as AstraZeneca's Iressa) and erlotinib (in the U.S. known as Genentech's Tarceva), future opportunities for Western companies will depend heavily on their pricing strategies and their patent protection in India. Moreover, monoclonal antibodies will surge and won't be copied successfully during the report's 2008 - 2013 forecast period.
"Opportunity for Western companies penetrating or wanting to penetrate India's non-small-cell lung cancer (NSCLC) drug market lies in forming alliances with Indian companies in order to negotiate the complex regulatory process of getting new NSCLC therapies to market," stated Manashi Sherawat, Ph.D., analyst at Decision Resources. "Opportunity also lies in raising awareness of this form of cancer in India's urban and rural sectors."
About Emerging Markets Reports
Emerging Markets is a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 email@example.com firstname.lastname@example.org
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Natalia Morales, Decision Resources, +1-781-296-2691,
email@example.com; or Elizabeth Marshall, Decision Resources, Inc.,
Web Site: http://www.decisionresources.com/